223 related articles for article (PubMed ID: 24606161)
1. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies.
Maybury CM; Jabbar-Lopez ZK; Wong T; Dhillon AP; Barker JN; Smith CH
Br J Dermatol; 2014 Jul; 171(1):17-29. PubMed ID: 24606161
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis.
Maybury CM; Samarasekera E; Douiri A; Barker JN; Smith CH
Br J Dermatol; 2014 Jun; 170(6):1237-47. PubMed ID: 24588075
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
Montaudié H; Sbidian E; Paul C; Maza A; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP
J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():12-8. PubMed ID: 21388454
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
Berends MA; Snoek J; de Jong EM; Van Krieken JH; de Knegt RJ; van Oijen MG; van de Kerkhof PC; Drenth JP
Liver Int; 2007 Jun; 27(5):639-45. PubMed ID: 17498249
[TBL] [Abstract][Full Text] [Related]
5. Detection of significant liver fibrosis in Chinese psoriasis patients receiving methotrexate: a comparison between transient elastography and liver histology.
Wong CSM; Mak LLY; Lee VKH; Lo RCL; Chung MMH; Chu F; Yeung CK; Yuen MF; Chan HHL
Hong Kong Med J; 2024 Apr; 30(2):110-119. PubMed ID: 38651202
[TBL] [Abstract][Full Text] [Related]
6. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
Langman G; Hall PM; Todd G
J Gastroenterol Hepatol; 2001 Dec; 16(12):1395-401. PubMed ID: 11851839
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.
Carneiro SC; Cássia FF; Lamy F; Chagas VL; Ramos-e-Silva M
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
Rattanakaemakorn P; Pinyowiwat P; Iamsumang W; Chanprapaph K; Suchonwanit P
Drug Des Devel Ther; 2021; 15():2299-2307. PubMed ID: 34093007
[TBL] [Abstract][Full Text] [Related]
9. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?
Aithal GP; Haugk B; Das S; Card T; Burt AD; Record CO
Aliment Pharmacol Ther; 2004 Feb; 19(4):391-9. PubMed ID: 14871278
[TBL] [Abstract][Full Text] [Related]
10. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?
Thomas JA; Aithal GP
Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-induced liver cirrhosis in a patient of psoriasis.
Avasthi G; Bhatt P; Singh J
J Assoc Physicians India; 2012 May; 60():47-8. PubMed ID: 23029724
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
Malatjalian DA; Ross JB; Williams CN; Colwell SJ; Eastwood BJ
Can J Gastroenterol; 1996 Oct; 10(6):369-75. PubMed ID: 9193771
[TBL] [Abstract][Full Text] [Related]
13. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up.
Zachariae H; Søgaard H; Heickendorff L
Dermatology; 1996; 192(4):343-6. PubMed ID: 8864370
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes.
Oogarah PK; Rowland PL; Mitchell DM; Smith A; Chalmers RJ; Rowan B; Haboubi NY
Br J Dermatol; 1995 Oct; 133(4):512-8. PubMed ID: 7577576
[TBL] [Abstract][Full Text] [Related]
16. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.
Zachariae H; Heickendorff L; Søgaard H
Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689
[TBL] [Abstract][Full Text] [Related]
17. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal.
Boffa MJ; Chalmers RJ; Haboubi NY; Shomaf M; Mitchell DM
Br J Dermatol; 1995 Nov; 133(5):774-8. PubMed ID: 8555032
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics.
Nyfors A
Acta Pathol Microbiol Scand A; 1977 Jul; 85(4):511-8. PubMed ID: 899789
[TBL] [Abstract][Full Text] [Related]
19. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
Atallah E; Grove JI; Crooks C; Burden-Teh E; Abhishek A; Moreea S; Jordan KM; Ala A; Hutchinson D; Aspinall RJ; Murphy R; Aithal GP
J Hepatol; 2023 May; 78(5):989-997. PubMed ID: 36702175
[TBL] [Abstract][Full Text] [Related]
20. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
